NeuroAge Therapeutics
About NeuroAge Therapeutics
NeuroAge Therapeutics utilizes machine learning algorithms to assess brain aging through cognitive testing, blood biomarkers, genetics, and MRI data, enabling personalized therapeutic recommendations. The company addresses the increasing risk of neurodegenerative diseases, such as Alzheimer's and Parkinson's, by developing targeted medications aimed at reversing biological brain aging.
```xml <problem> The aging process increases the risk of neurodegenerative diseases like Alzheimer's and Parkinson's, impacting cognitive function and overall brain health. Current methods for assessing brain aging are often limited, hindering early detection and personalized intervention strategies. </problem> <solution> NeuroAge Therapeutics offers a comprehensive brain-aging assessment platform that utilizes artificial intelligence to analyze cognitive test results, blood biomarkers, genetic data, and MRI scans. By integrating these diverse data sources, NeuroAge provides individuals with a personalized "brain age" metric and identifies potential risks for future neurodegenerative conditions. The platform then generates tailored recommendations, including lifestyle adjustments and potential therapeutic interventions, designed to slow down or even reverse the biological processes of brain aging. This approach enables proactive management of cognitive health and facilitates the development of targeted therapeutics for age-related neurological disorders. </solution> <features> - AI-powered analysis of cognitive performance through online NeuroGames - Integration of blood biomarker data to identify age-related physiological changes - Genetic risk assessment for predisposition to neurodegenerative diseases - Quantitative analysis of brain MRI scans to detect structural changes - Personalized "brain age" calculation and risk stratification - Neuprint Protocol: Personalized brain health tele-coaching with a skilled therapist with a degree in Neuroscience from MIT. - Lifestyle recommendations based on the "Nine Pillars of Health Brain Aging" - Identification of potential therapeutic targets for reversing brain aging </features> <target_audience> The primary target audience includes individuals concerned about their cognitive health and risk of neurodegenerative diseases, as well as clinicians and researchers focused on developing and implementing interventions to promote healthy brain aging. </target_audience> ```
What does NeuroAge Therapeutics do?
NeuroAge Therapeutics utilizes machine learning algorithms to assess brain aging through cognitive testing, blood biomarkers, genetics, and MRI data, enabling personalized therapeutic recommendations. The company addresses the increasing risk of neurodegenerative diseases, such as Alzheimer's and Parkinson's, by developing targeted medications aimed at reversing biological brain aging.
Where is NeuroAge Therapeutics located?
NeuroAge Therapeutics is based in San Francisco, United States.
When was NeuroAge Therapeutics founded?
NeuroAge Therapeutics was founded in 2022.
How much funding has NeuroAge Therapeutics raised?
NeuroAge Therapeutics has raised 200000.
Who founded NeuroAge Therapeutics?
NeuroAge Therapeutics was founded by Salah Mahmoudi.
- Salah Mahmoudi - CEO / Co-founder
- Location
- San Francisco, United States
- Founded
- 2022
- Funding
- 200000
- Employees
- 7 employees
- Major Investors
- Alzheimer's Drug Discovery Foundation